

Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/LC963508BA54EN.html>

Date: May 2022

Pages: 65

Price: US\$ 2,000.00 (Single User License)

ID: LC963508BA54EN

Abstracts

Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 11 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Lassa Fever (Lassa Hemorrhagic Fever) - Overview
- Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
 - Curevac NV
 - Emergent BioSolutions Inc
 - FUJIFILM Toyama Chemical Co Ltd
 - GeoVax Labs Inc
 - Globavir Biosciences Inc
 - Helix Biogen Institute
 - ImmunityBio Inc
 - Inovio Pharmaceuticals Inc
 - Kineta Inc
 - Themis Bioscience GmbH
 - Tonix Pharmaceuticals Holding Corp
 - Zalgen Labs LLC
- Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
 - (Ebola + Lassa Fever + Marburg) vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action
 - (Lassa fever + rabies) vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action
 - arevirumab-3 - Drug Profile
 - Product Description

Mechanism Of Action
History of Events
favipiravir - Drug Profile
Product Description
Mechanism Of Action
History of Events
GBV-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GEOLM-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
hemorrhagic fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
INO-4500 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action

History of Events

Lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

lassa fever vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

lassa vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

LHF-535 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ML-29 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Lassa Fever - Drug Profile

Product Description

Mechanism Of Action

TNX-3500 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Infectious Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects

Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones

Featured News & Press Releases

Oct 26, 2021: INOVIO completes enrollment of phase 1B clinical trial for its DNA vaccine candidate against Lassa fever, INO-4500, in West Africa

Jul 14, 2021: Batavia successfully uses innovative hip-vax to manufacture IAVI's lassa fever vaccine candidate for phase I clinical trials

Jun 15, 2021: EDCTP and CEPI Funding moves IAVI's lassa fever vaccine candidate into advanced clinical development

Feb 23, 2021: INOVIO announces first subject dosed in phase 1B clinical trial for its DNA vaccine against lassa fever, INO-4500, in West Africa

Mar 25, 2020: Kineta presents clinical study results of LHF-535 at the International Conference on Antiviral Research (ICAR)

Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine

Aug 06, 2019: Kineta Secures \$1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535

Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data

Jul 15, 2019: Kineta secures NIAID grant worth up to \$5.8M to evaluate LHF-535 in Arenaviruses

May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500

Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

Sep 26, 2018: GeoVax awarded \$2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine

Sep 15, 2018: Advanced preclinical development and production of master seed virus of GEO-LM01, a novel MVA-VLP vaccine against Lassa Fever

Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever

Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Curevac NV, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Globavir Biosciences Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Helix Biogen Institute, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by ImmunityBio Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, 2022

Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/LC963508BA54EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LC963508BA54EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

